Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial: Annals of Internal Medicine: Vol 0, No 0 acpjournals.org/doi/10.7326/M2…

Its taken 8 years to publication today! Thanks to the colleagues, funders and patients who made this possible. 3fold fewer #lupus flares with belimumab after Rituximab Versus Arthritis⁩ ⁦NIHR UCLH Biomedical Research Centre⁩ ⁦GSK⁩ ⁦UCL⁩ ⁦LUPUSUK 💙⁩ acpjournals.org/doi/10.7326/M2…

New this week: An #RCT from Michael Ehrenstein UCL News suggests that a new drug treatment pattern reduced disease symptoms by 3x for patients with persistent, acute #lupus. Ehrenstein Lab UCL ow.ly/L6WQ50GxHiL

A must read for anyone planning an RCT in #lupus in UK!

Congratulations to muhammad shipa for receiving his Junior Investigator Award👏 UCL Faculty of Medical Sciences UCL DoM Early Careers ucl.ac.uk/medicine/news/…

Well done muhammad shipa, this is for BEAT-lupus so thanks again to the whole team who were involved..see acpjournals.org/journal/aim/ju… data from the trial to be presented at #EULAR2022 in the #Lupus oral abstract session on Friday

Congratulations to muhammad shipa for receiving the Annals of Internal Medicine Junior Investigator Award for his publication of the BEAT-LUPUS RCT data, “Effectiveness of belimumab after rituximab in SLE” acpjournals.org/doi/10.7326/M2… Michael Ehrenstein

Very proud of my two clinical fellows who are giving talks at #EULAR2022. Su-Ann Yeoh tomorrow at 4.30 about #rheumatoid arthritis and muhammad shipa on #lupus and biomarkers from the BEAT-lupus trial on Friday at 10.30.

SLE pathogenesis: muhammad shipa from Ehrenstein Lab UCL shows that high levels of serum IgA2 anti-dsDNA antibodies can predict response to #belimumab after rituximab in #lupus patients, but high serum IL-6 levels is a negative predictor of response. #EULAR2022 #RheumTwitter #SLE

Well done to muhammad shipa from the Ehrenstein Lab UCL for his interesting lab data from the Beat Lupus #sle trial at the UCL Division of Medicine Research Retreat today #LUPUS

A lovely day spent at the UCLH Rheumatology Research Open Day organised by UCLH Patient Partners in Rheumatology Research with patient partners learning about the research questions which are important to them. Grateful for the opportunity to share our research today! muhammad shipa Su-Ann Yeoh

Could a simple blood test, IgA2 anti-dsDNA antibodies, identify #lupus patients who will respond to #belimumab after #rituximab therapy? Biomarker analyses of the BEAT-lupus trial. muhammad shipa Liliana Ribeiro dos Santos Versus Arthritis GSK NIHR UCLH Biomedical Research Centre authors.elsevier.com/sd/article/S26…

An excellent talk by Michael Ehrenstein about new treatments and approaches to target B cells and BAFF in #lupus. #BSR23

Well done to muhammad shipa on your talk at the #BSR23 on #biomarkers of response to belimumab and rituximab combination - results from the BEAT-LUPUS #SLE trial

Very proud of muhammad shipa who successfully defended his thesis this afternoon. Well done! Thanks to Versus Arthritis and LUPUSUK 💙 for supporting his research.